BusinessNeos Therapeutics to Present at BMO Prescription for Success Healthcare ConferenceBy Nasdaq OMXDec 7, 2016, 1:00 PM UTC
BusinessNeos Therapeutics Submits NDA for Amphetamine Extended-Release Liquid Suspension Drug Candidate, NT-0201, for the Treatment of ADHDBy Nasdaq OMXNov 17, 2016, 1:00 PM UTC
BusinessNeos Therapeutics Reports Third Quarter 2016 Financial ResultsBy Nasdaq OMXNov 10, 2016, 12:00 PM UTC
BusinessNeos Therapeutics to Present at Stifel 2016 Healthcare ConferenceBy Nasdaq OMXNov 8, 2016, 1:00 PM UTC
BusinessNeos Therapeutics to Host Third Quarter 2016 Financial Results Conference Call on November 10, 2016By Nasdaq OMXNov 3, 2016, 12:01 PM UTC
